Publications by authors named "J Lavee"
Xenotransplant covers a broad ethical territory and there are several ethical questions that have arisen in parallel with the technological advances that have allowed the first porcine transplants to occur. This brief communication highlights ethical considerations regarding heart and lung xenotransplantation, with an emphasis on unresolved value-based concerns in the field. The aim of this text is therefore to encourage the readers to consider the vast potential of this emerging technique to do good, but also the risk of doing harm, and to participate in a discussion.
View Article and Find Full Text PDFArticle Synopsis
- Long-term support with the HeartMate 3 (HM3) left ventricular assist device (LVAD) has improved outcomes for end-stage heart failure patients, but there's limited data on those who had simultaneous cardiac surgeries during the procedure.
- In a study of 131 patients between December 2016 and April 2022, 23 underwent concomitant cardiac surgical procedures (CCSP) while receiving HM3-LVAD, while 108 had only the HM3-LVAD implanted.
- Results showed no significant differences in 30-day, 6-month, and 12-month mortality rates between the CCSP group and the HM3-only group, indicating that simultaneous surgeries do not adversely affect survival when getting an HM3-L
Background And Aims: HeartMate 3 (HM3) is a fully magnetically levitated continuous flow left ventricular assist device, which received CE marking in 2015. The ELEVATE Registry was initiated to collect real-world outcomes in patients treated with HM3 post-CE Mark approval.
Methods: A total of 540 subjects implanted at 26 centres between March 2015 and February 2017 were included in this registry.